Phenotypic characterization of transgenic mice harboring Nf1+/- or Nf1-/- osteoclasts in otherwise Nf1+/+ background

Journal of Cellular Biochemistry

Volumn 113, Issue 6, 2012, Pages 2136-2146

  Alanne, Maria H ^a   Siljamäki, Elina ^a,b   Peltonen, Sirkku ^a,c   Väänänen, Kalervo ^a   Windle, Jolene J ^d   Parada, Luis F ^e   Määttä, Jorma A ^a   Peltonen, Juha ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

ACTIN RING; BONE DYNAMICS; CTX; OSTEOCLASTOGENESIS; Ras Erk PATHWAY

Indexed keywords

NEUROFIBROMIN;

ACTIN FILAMENT; ANIMAL TISSUE; ARTICLE; BONE FRAGILITY; CELL SHAPE; CONTROLLED STUDY; CORTICAL BONE; FEMALE; GROWTH PLATE; MALE; MEGAKARYOCYTE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PHENOTYPE; PRIORITY JOURNAL; SPLEEN SIZE; TIBIA; TRABECULAR BONE; TRANSGENIC MOUSE;

ANIMALS; BONE AND BONES; BONE RESORPTION; DISEASE MODELS, ANIMAL; FEMALE; GENOTYPE; GROWTH PLATE; MALE; MEGAKARYOCYTES; MICE; MICE, TRANSGENIC; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; OSTEOCLASTS; PHENOTYPE; SPLEEN;

MUS; MUS MUSCULUS;

EID: 84859571459     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24088     Document Type: Article

References (41)

1. Biskobing DM, Fan X, Rubin J,. 1995. Characterization of MCSF-induced proliferation and subsequent osteoclast formation in murine marrow culture. J Bone Miner Res 10: 1025-1032.
2. Bord S, Frith E, Ireland DC, Scott MA, Craig JI, Compston JE,. 2004. Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. Br J Haematol 126: 244-251.
3. Bord S, Frith E, Ireland DC, Scott MA, Craig JI, Compston JE,. 2005. Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL. Bone 36: 812-819.
4. Bradley E, Oursler M,. 2008. Osteoclast culture and resorption assays. Methods Mol Biol 455: 19-35.
5. Brannan C, Perkins A, Vogel K, Ratner N, Nordlund M, Reid S, Buchberg A, Jenkins N, Parada L, Copeland N,. 1994. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 8: 1019-1029.
6. Buchberg AM, Cleveland LS, Jenkins NA, Copeland NG,. 1990. Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway. Nature 347: 291-294.
7. Dossa T, Arabian A, Windle JJ, Dedhar S, Teitelbaum SL, Ross FP, Roodman GD, St-Arnaud R,. 2010. Osteoclast-specific inactivation of the integrin-linked kinase (ILK) inhibits bone resorption. J Cell Biochem 110: 960-967.
8. Elefteriou F, Benson M, Sowa H, Starbuck M, Liu X, Ron D, Parada L, Karsenty G,. 2006. ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab 4: 441-451.
9. Elefteriou F, Kolanczyk M, Schindeler A, Viskochil D, Hock J, Schorry E, Crawford A, Friedman J, Little D, Peltonen J, Carey J, Feldman D, Yu X, Armstrong L, Birch P, Kendler D, Mundlos S, Yang F, Agiostratidou G, Hunter-Schaedle K, Stevenson D,. 2009. Skeletal abnormalities in neurofibromatosis type 1: Approaches to therapeutic options. Am J Med Genet A 149A: 2327-2338.
10. Feng X,. 2005. RANKing intracellular signaling in osteoclasts. IUBMB Life 57: 389-395.
11. Garimella R, Kacena MA, Tague SE, Wang J, Horowitz MC, Anderson HC,. 2007. Expression of bone morphogenetic proteins and their receptors in the bone marrow megakaryocytes of GATA-1(low) mice: A possible role in osteosclerosis. J Histochem Cytochem 55: 745-752.
12. Hasle H, Nir M, Tommerup N,. 1997. Prolonged extreme thrombocytosis associated with neurofibromatosis type 1. J Pediatr 130: 317-319.
13. Heervä E, Alanne M, Peltonen S, Kuorilehto T, Hentunen T, Väänänen K, Peltonen J,. 2010. Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity, aberrant morphology, and resistance to serum deprivation. Bone 47: 583-590.
14. Hogan B, Beddington R, Constatini F, Lacy E,. 1994. Techniques for visualizing gene products, cells, tissues, and organ systems. In:, Nagy A, Gertsenstein M, Vintersten K, Behringer R, editors. Manipulating the mouse embryo: A laboratory manual. Woodbury, NY: Cold Spring Harbor Laboratory Press. pp. 699-701.
15. Jacks T, Shih T, Schmitt E, Bronson R, Bernards A, Weinberg R,. 1994. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 7: 353-361.
16. Jouhilahti EM, Peltonen S, Heape AM, Peltonen J,. 2011. The pathoetiology of neurofibromatosis 1. Am J Pathol 178: 1932-1939.
17. Kim H, Rosenbaum T, Marchionni M, Ratner N, DeClue J,. 1995. Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes. Oncogene 11: 325-335.
18. Kolanczyk M, Kossler N, Kühnisch J, Lavitas L, Stricker S, Wilkening U, Manjubala I, Fratzl P, Spörle R, Herrmann B, Parada L, Kornak U, Mundlos S,. 2007. Multiple roles for neurofibromin in skeletal development and growth. Hum Mol Genet 16: 874-886.
19. Kossler N, Stricker S, Rödelsperger C, Robinson PN, Kim J, Dietrich C, Osswald M, Kühnisch J, Stevenson DA, Braun T, Mundlos S, Kolanczyk M,. 2011. Neurofibromin (Nf1) is required for skeletal muscle development. Hum Mol Genet 14: 2697-2709.
20. Kuorilehto T, Nissinen M, Koivunen J, Benson M, Peltonen J,. 2004. NF1 tumor suppressor protein and mRNA in skeletal tissues of developing and adult normal mouse and NF1-deficient embryos. J Bone Miner Res 19: 983-989.
21. Kuorilehto T, Ekholm E, Nissinen M, Hietaniemi K, Hiltunen A, Paavolainen P, Penttinen R, Peltonen J,. 2006. NF1 gene expression in mouse fracture healing and in experimental rat pseudarthrosis. J Histochem Cytochem 54: 363-370.
22. Le DT, Kong N, Zhu Y, Lauchle JO, Aiyigari A, Braun BS, Wang E, Kogan SC, Le Beau MM, Parada L, Shannon KM,. 2004. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood 103: 4243-4250.
23. Leskelä H, Kuorilehto T, Risteli J, Koivunen J, Nissinen M, Peltonen S, Kinnunen P, Messiaen L, Lehenkari P, Peltonen J,. 2009. Congenital pseudarthrosis of neurofibromatosis type 1: Impaired osteoblast differentiation and function and altered NF1 gene expression. Bone 44: 243-250.
24. Ma J, Li M, Hock J, Yu X,. 2012. Hyperactivation of mTOR critically regulates abnormal osteoclastogenesis in neurofibromatosis Type 1. J Orthop Res 30: 144-152.
25. McLeod M,. 1980. Differential staining of cartilage and bone in whole mouse fetuses by alcian blue and alizarin red S. Teratology 22: 299-301.
26. Parfitt A, Drezner M, Glorieux F, Kanis J, Malluche H, Meunier P, Ott S, Recker R,. 1987. Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2: 595-610.
27. Peng Z, Tuukkanen J, Zhang H, Jämsä T, Väänänen HK,. 1994. The mechanical strength of bone in different rat models of experimental osteoporosis. Bone 15: 523-532.
28. Riccardi V, Eichner J,. 1986. Neurofibromatosis: Phenotype, natural history and pathogenesis. Baltimore, MD: Johns Hopkins University Press.
29. Rodan GA, Martin TJ,. 1981. Role of osteoblasts in hormonal control of bone resorption-a hypothesis. Calcif Tissue Int 33: 349-351.
30. Sherman L, Atit R, Rosenbaum T, Cox A, Ratner N,. 2000. Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts. J Biol Chem 275: 30740-30745.
31. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ,. 1997. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89: 309-319.
32. Stevenson D, Viskochil D, Carey J, Slater H, Murray M, Sheng X, D'Astous J, Hanson H, Schorry E, Moyer-Mileur L,. 2009. Tibial geometry in individuals with neurofibromatosis type 1 without anterolateral bowing of the lower leg using peripheral quantitative computed tomography. Bone 44: 585-589.
33. Suva LJ, Hartman E, Dilley JD, Russell S, Akel NS, Skinner RA, Hogue WR, Budde U, Varughese KI, Kanaji T, Ware J,. 2008. Platelet dysfunction and a high bone mass phenotype in a murine model of platelet-type von Willebrand disease. Am J Pathol 172: 430-439.
34. Villeval JL, Cohen-Solal K, Tulliez M, Giraudier S, Guichard J, Burstein SA, Cramer EM, Vainchenker W, Wendling F,. 1997. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 90: 4369-4383.
35. Wang W, Nyman JS, Ono K, Stevenson DA, Yang X, Elefteriou F,. 2011. Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I. Hum Mol Genet 20: 3910-3924.
36. Xu GF, O'Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, Dunn D, Stevens J, Gesteland R, White R,. 1990. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 62: 599-608.
37. Yang F, Chen S, Robling A, Yu X, Nebesio T, Yan J, Morgan T, Li X, Yuan J, Hock J, Ingram D, Clapp D,. 2006. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest 116: 2880-2891.
38. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T,. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 3597-3602.
39. Yu X, Chen S, Potter O, Murthy S, Li J, Pulcini J, Ohashi N, Winata T, Everett E, Ingram D, Clapp W, Hock J,. 2005. Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning. Bone 36: 793-802.
40. Zhang W, Rhodes SD, Zhao L, He Y, Zhang Y, Shen Y, Yang D, Wu X, Li X, Yang X, Park SJ, Chen S, Turner C, Yang FC,. 2011. Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model. Bone 48: 1378-1387.
41. Zhu Y, Romero M, Ghosh P, Ye Z, Charnay P, Rushing E, Marth J, Parada L,. 2001. Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev 15: 859-876.